Sugammadex binds and inactivates the aminosteroid nondepolarizing muscle relaxants rocuronium and vecuronium. Sugammadex is available in 50 countries, but the United States is not one of them. The US Food and Drug Administration turned down approval for the drug in 2008 because it sought more information concerning allergic reactions and bleeding events. Approval was also denied in the 3rd quarter last year due to concerns about a hypersensitivity study. Hopefully sugammadex will be available here soon. In clinical situations, three drugs have been shown to displace rocuronium from sugammadex: toremifene, a selective estrogen receptor modulator used to treat patients with breast cancer, fusidic acid, an antibiotic that inhibits translocation during protein synthesis, and flucloxacillin, an antibiotic analog of cloxacillin. None of these are commonly used in anesthesia or postoperative care, and so it seems unlikely that this could be an important clinical problem...